Logo image
Sign in
Back
Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
Journal article   Peer reviewed

Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial

Alexander B. Olawaiye, Laurence Gladieff, David M. O'Malley, Jae-Weon Kim, Gabriel Garbaos, Vanda Salutari, Lucy Gilbert, Linda Mileshkin, Alix Devaux, Elizabeth Hopp, …
Obstetrical & gynecological survey, Vol.80(10), pp.636-638
10/2025
DOI: https://doi.org/10.1097/01.ogx.0001169628.43305.4c

Abstract

(Abstracted from Lancet 2025;405(10496):2205-2216) Deaths related to ovarian cancer were estimated at 207,000 in 2020 across the globe. An approximate 70% of patients have relapses of the disease after platinum-based chemotherapy as they develop resistance to the treatment; platinum-resistant ovarian cancer can be treated with nonplatinum chemotherapy with or without bevacizumab.

Metrics

6 Record Views

Details

Logo image